NeRRe Therapeutics

Optimizing a unique (NK)-1 neurokinin antagonist pipeline

NeRRe Therapeutics is a UK based clinical-stage company developing a unique pipeline of three neurokinin (NK)-1 antagonists for the treatment of common, chronic and debilitating conditions caused by neuronal hypersensitivity. The lead compound orvepitant, a potent and highly selective NK-1 receptor antagonist, is in a Phase 2b multinational trial to assess its benefit in patients with chronic refractory cough. It has the potential to be a first-in-class once-daily oral therapy, bringing significant benefits to sufferers of this incapacitating condition for which there are currently no approved medicines.

  • CEO Dr Mary Kerr
  • Industry Biotech